Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.